RA Capital Management

We are excited to announce the first acquisition of a fully-baked company from RA Capital's RAVen (RA Ventures) incubator - congratulations to the Mariana Oncology team! You can read more about how RAVen helped build the company that became Mariana in the RApport article below. https://lnkd.in/eQmjvZQu

Celebrating #EarthWeek at the White House! RA Capital Management’s General Counsel Sarah Reed and I were thrilled to be involved in the development of the US-BOLT (University Startup Basic-Out-Licensing) term sheet for climate-related startups spinning out of universities. The goal of the work is to make it easier for universities and start-up companies to collaborate on the commercialization of game-changing technologies. Together with the work group led by Orin Herskowitz, the White House Office of Science and Technology Policy celebrated the completion of this effort with fellow professionals, policymakers, and innovators, all dedicated to driving positive change for our planet. We are excited to have the US-BOLT Climate term sheet now available to the community on the NVCA website here: https://lnkd.in/e5hsXfQw Joshua Posamentier (Congruent); Manny Stockman and Kirsten Leute (OUP); Gabriel Kra and Carly Anderson (Prelude); Christina Karapataki (Breakthrough Energy Ventures); Orin Herskowitz and Dovina Qu (Columbia); Case Cortese and Rosemary Kiser (Caltech); Deirdre Zammit (MIT); Jordan Grant and Sam Liss (Harvard); Fiona Wills (University of Washington); Jonathan Gortat, MBA, CLP (Stanford); Anthony Williams (Princeton); Laleh Shayesteh (Berkeley); Geoffrey Spolyar (Cooley); Sarah A. Solomon (Goodwin): Miranda Biven, Barath Chari, Manja Sachet, Farah Gerdes (Wilson Sonsini)

Thank you, Kendalle Burlin O'Connell, Esq. and the MassBio team for convening such an inspirational and informative day #StateOfPossible2024! I was honored to speak with an engaged audience about how Massachusetts can lengthen its lead as the center of biomedical innovation by inspiring “fans” with our quests to develop new therapies and being a model for insurance reform.  Great messages from my fellow speakers including Governor Maura Healey, Congressman Jake Auchincloss, Biotechnology Innovation Organization John F. Crowley, Reshma Kewalramani, MD FASN, CEO of Vertex Pharmaceuticals, and former NFL player and advocate Devin McCourty. Together, we make Massachusetts the state where innovation happens! #biomedicalinnovation #biotech #massbio #stateofpossible #creatingfans RA Capital Management Peter Kolchinsky

It was a full house yesterday at the Broad Institute of MIT and Harvard for our 2024 #Science2Startup symposium. Thank you to everyone who joined us for a day filled with insightful presentations, engaging panel discussions, and valuable networking opportunities centered around the future of the #biotech industry.   Boston's vibrant #lifescience ecosystem makes this an unparalleled hub for innovation and we are thrilled to continue our efforts to drive scientific breakthroughs and entrepreneurial ventures forward. On the RA team, we'd specifically like to thank Joshua Resnick for participating as an Advisor and Rebecca Silberman, Jenna Hebert, PhD, and Jessica Sagers, PhD for their work on the Steering Committee.   Stay tuned for details on next year's event!   Atlas Venture │ 5AM Ventures │ Osage University Partners (OUP) │ RA Capital Management │ MassBio │ Colliers │ Deloitte │ Evotec │ Goodwin │ Pliancy │ Silicon Valley Bank

The 2024 #Science2Startup symposium is tomorrow! After exciting discussions and powerful networking, eight researchers will present their ideas and interact with leading investors and executives in the Boston #biotech hub. Thank you to our other event hosts F-Prime Capital, Atlas Venture, 5AM Ventures, Osage University Partners (OUP), and MassBio. Make sure to follow along for updates!

We are delighted to welcome David R. Liu, Ph.D. to lead our fireside chat at this year’s #Science2Startup symposium in Cambridge, MA on April 10th.    Liu is the Richard Merkin Professor, Director of the Merkin Institute of Transformative Technologies in Healthcare, and Vice-Chair of the Faculty at the Broad Institute of MIT and Harvard; Thomas Dudley Cabot Professor of the Natural Sciences & Professor of Chemistry and Chemical Biology at Harvard University; and Howard Hughes Medical Institute Investigator.   His major research interests include the engineering, evolution, and in vivo delivery of genome editing agents to study and treat genetic diseases; the evolution of novel therapeutic proteins using phage-assisted continuous evolution (PACE); and the discovery of bioactive synthetic molecules using DNA-templated organic synthesis and DNA-encoded libraries.   As a business leader, he has successfully launched, led and scaled companies and products in the #healthcare space.   Learn more about Science2Startup, a unique event where entrepreneurs and researchers in the biotech space can meet, collaborate, and learn from one another: www.science2startup.com   If you'd like to get involved, email us at: info@science2startup.com

We can't wait to host this year's #Science2Startup, where eight presenters from leading global academic institutions will present their startup ideas to fellow #biotech investors and industry executives. To learn more about the event or get involved, email us at info@science2startup.com or visit www.science2startup.com.

Hat tip to RA Capital Management's visionary GC Sarah Reed, who saw an innovation bottleneck in startup documentation and standardization back in the early aughts and convened stakeholders to create a new industry standard. The National Venture Capital Association model docs she created and put out to the world in December 2003 have changed the way the industry works - but don’t just take our word for it. A recent study by Stanford Law Professor Robert Bartlett showed NVCA model doc usage related to issuing charters connected to startup Series A financings rose from 3% in 2004 to nearly 85% in 2022. Sarah Reed’s work to set the standard for standardization is one reason why The Deal's David Marcus wrote last week in “Save the Money for the Company: Standardizing VC Contracts” that those model docs are “one of the great achievements in American corporate law in this century.” They “streamlined the legal work involved in early-stage startups and allowed for the evolution of more complex financing structures." Go Sarah! At RA Capital, we all try to improve everything... board governance, IPO process, the Inflation Reduction Act, insurance reform, healthcare economics literacy, and standardized legal documents… because we believe everything can be improved. Are you an entrepreneur driven to fix something about the world and looking to work with like-minded people? Reach out! National Venture Capital Association The Deal #legalinnovation #legalinsights #futureoflaw https://lnkd.in/e2hYibsi

Mark your calendars: #Science2Startup 2024 is happening on April 10th. We are thrilled to be working alongside F-Prime Capital, Atlas Venture, 5AM Ventures, Osage University Partners (OUP), and MassBio on this event, as well as sponsors Colliers, Deloitte, Evotec, Goodwin, Pliancy, and Silicon Valley Bank. Thank you for bringing entrepreneurs and researchers together with top #biotech and #pharma execs, VCs, and scientists. Boston is a uniquely rich area for #lifescience and we are excited to work together to continue the tradition of excellence.   Read our official announcement: https://lnkd.in/eZxamvPr

Thank you to Colliers, Evotec, Goodwin, Pliancy, and Silicon Valley Bank - the sponsors who are making this year’s #Science2Startup event happen! We’re looking forward to coming together in April at the Broad Institute to connect entrepreneurs with leading scientists, researchers, and top investors.       Learn more about the symposium, the advisors, and the firms supporting the future of the #biotech industry here: www.science2startup.com